

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

Guselkumab for previously treated moderately to severely active Crohn's disease [ID6238]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
	<p>Yes, the company noted during consultation that inflammatory bowel disease may be classed as a disability depending on the effect it has on a person's daily life.</p> <p>It also noted that an additional treatment option which can be administered at home may reduce inequalities and increase adherence for people with inflammatory bowel disease.</p>
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
	<p>Where appropriate, the committee may consider whether its recommendation could result in less favourable treatment for reasons related to a person's disability.</p> <p>Where appropriate, the committee may consider whether there are additional benefits that have not been captured in the economic modelling.</p>
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
	No

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
	No

Approved by Associate Director (name): Janet Robertson

Date: 13 January 2025